摘要
破裂颅内动脉瘤是一种高致死率和高致残率的脑血管急症,虽然支架辅助弹簧圈栓塞术有效,但术中血栓形成和术后出血等并发症问题依然突出。替罗非班作为一种强效的血小板聚集抑制剂,以其迅速起效、半衰期短且血小板功能可快速恢复等特点,在破裂颅内动脉瘤治疗中显示出潜力。本综述通过总结替罗非班的药理学机制及其临床应用,分析其在不同剂量下的疗效与安全性,并探讨其在术前预防性用药和术中挽救性治疗中的合理用药策略。此外,本文还重点讨论了替罗非班在治疗破裂颅内动脉瘤中的挑战与局限,提出了未来研究方向,以期为替罗非班的标准化应用提供循证支持,提升其在神经介入治疗中的应用价值。
Ruptured intracranial aneurysm is a cerebrovascular emergency with high mortality and morbidity.Although stent-assisted coil embolization is effective,complications such as intraoperative thrombosis and postoperative bleeding remain prominent issues.Tirofiban,a potent platelet aggregation inhibitor,with its rapid onset,short half-life,and quick recovery of platelet function,shows potential in the treatment of ruptured intracranial aneurysms.This review summarizes the pharmacological mechanisms of tirofiban and its clinical applications,analyzes its efficacy and safety at different doses,and explores its rational use in preoperative prophylaxis and intraoperative salvage therapy.Furthermore,the review discusses the challenges and limitations of using tirofiban in the treatment of ruptured intracranial aneurysms and proposes future research directions.The goal is to provide evidence-based support for the standardized application of tirofiban and enhance its value in neurointerventional therapy.
作者
杨立
郑治
孟旭峰
刘倩
郝云飞
YANG Li;ZHENG Zhi;MENG Xufeng;LIU Qian;HAO Yunfei(The First Clinical College of Gansu University of Traditional Chinese Medicine,Lanzhou 730000,Gansu,China;Department of Cerebrovascular Diseases,Gansu Provincial People's Hospital,Lanzhou 730000,Gansu,China)
出处
《中国临床药理学与治疗学》
北大核心
2026年第1期107-115,共9页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
甘肃省自然科学基金项目(20JR10RA384)
科技创新平台基金项目(21GSSYB-13)
甘肃省人民医院脑血管病重点实验室(20JR10RA431)。
